Pertussis in Adolescents and Adults: Should We Vaccinate?

Tracy Lieu, MD, MPH

Department of Ambulatory Care and Prevention




Harvard Pilgrim Health Care and Harvard Medical School




Messages

- Pertussis in adolescents and adults is increasing and costly
- Vaccination <u>could</u> be beneficial and cost-effective
- Need better data on incidence

Reported Pertussis Cases U.S, 1922-2000




Reported Pertussis Cases U.S., 1980-2000




Pertussis in Infants

- Last year: 19 deaths, all infants
- Incidence in infants increasing
- Suggests pertussis circulation is increasing

Who Infects Infants?



Reported Pertussis Cases by Age U.S., 1983-2000







September 10, 2001

Whooping Cough Makes Comeback, Striking Teens and Young Adults ASSOCIATED PRESS

June 6, 2002

Whooping Cough Returns To U.S. as Immunity Wanes

By MARILYN CHASE

Acellular Pertussis Vaccines for Adolescents and Adults

- Licensed in Canada, Germany, Australia, France
- Combined with Td \rightarrow TdaP
- U.S. trial suggests effective

Why Is This Not a Slam Dunk?

- Vaccination risks should be weighed
- Immunity wanes
- Vaccine price is as yet unknown
- Vaccine coverage is hard to attain


Programmatic Options

- Adolescents
- Adolescents + boosters every 10 years
- Adults at 20 years old
- Adults at 20 years old + boosters every 10 years



Joint Initiative in Vaccine Economics (JIVE)





Cost-effectiveness analyses of policy options for pertussis, influenza, polio, and hepatitis B Cost-Effectiveness of Adolescent & Adult Pertussis Vaccination in the U.S.

Grace M. Lee, MD, MPH, Stephanie Schauer, PhD, Susan Lett, MD MPH, Charles LeBaron, MD, MPH, Trudy Murphy, MD, Tracy Lieu, MD, MPH, and collaborators

Children's Hospital Boston, Massachusetts Department of Public Health, Centers for Disease Control & Prevention, and Harvard Medical School

Acknowledgments

NIP/Immunization Services Division Lance Rodewald, Abigail Shefer, Donna Rickert, Shannon Stokely

NIP/Epidemiology and Surveillance Division Melinda Wharton, Trudy Murphy, Kris Bisgard, Charles LeBaron, James Singleton, John Glasser, Peng-Jun Lu


Expert panel

Kris Bisgard, Kathy Edwards, Scott Halperin, Susan Lett, Colin Marchant, Margaret Rennels, Joel Ward, Melinda Wharton


Questions


- Do the health benefits outweigh the vaccine risks?
- Will vaccination save money?
- Will it be cost-effective, relative to other health interventions?

Cost-Effective **#** Cost-Saving




Vaccines Are Cost-Effective





Outcomes of Pertussis




Pertussis Probabilities Base Case able Estimate

Variable

Incidence of pertussis Adolescents Adults

114 per 100,000 8 per 100,000

Pneumonia after pertussisAdolescents1%Adults3%



Vaccine Probabilities **Base Case** Variable **Estimate** Vaccine coverage: Adolescents 78% Adults 40% Vaccine adverse events: 22% Local **Systemic** 5% Vaccine effectiveness 92% [30-95%]

Preliminary Results: Health Outcomes*

Preliminary Results: Health Outcomes*				
Policy	Cases Prevented	Vaccine Adverse Events (mostly local)		
Adolescents	23,000	840,000		
Adols + boosters	27,000	2.6 million		
Adults at 20 yrs	920	440,000		
Adults + boosters	3600	1.8 million		

*For 2002 birth cohort assuming 100% surveillance & no change in infant transmission

Dilemmas


- How should we weigh preventing pertussis, vs. avoiding vaccine adverse events?
- Pertussis vaccination prevents few deaths
- Use time trade-off questions to get econometric measure -- qualityadjusted life-years

Time Trade-Off

Example: <u>Severe cough</u>

How many days or weeks would you be willing to give up from the end of your life to avoid severe cough for 8 weeks? The cough can cause vomiting several times a week, difficulty eating or drinking, and difficulty sleeping.

Values



Do Health Benefits Outweigh Vaccine Risks?

Do Health Benefits Outweigh Vaccine Risks?			
Policy option	If <u>NO</u> infant disease prevented	If <u>ALL</u> infant disease prevented	
Adolescents	Yes	Yes	
Adols + boosters	Yes	Yes	
Adults at 20 yrs	No	Yes	
Adults + boosters	No	No	

Questions


- Do the health benefits outweigh the vaccine risks?
- Will vaccination save money?
- Will it be cost-effective, relative to other health interventions?

Costs of Pertussis in Adolescents & Adults

Massachusetts

Analysis of Medical Costs

- Retrospective analysis
- 2,800 cases of confirmed pertussis in Massachusetts, 1998-2000
- Utilization of health services
- Costs of services from national sources



Survey on Non-Medical Costs

- Include work-loss and other expenses
- Psychological costs
- Telephone interviews
- 400 adolescent and adult cases

Non-Medical Costs Are High

	Cost		
		Non-	
<u>Age group</u>	Medical	<u>medical</u>	
Adolescent	300	60% x medical	
Adult	>300	150% x medical	

Cost of Vaccination?

Vaccine price = ? Vaccine administration = 0 if added to Td Program costs = ?

Temporary assumption: \$25

Cost of vaccination = \$25 Will Vaccination Save Money? Probably not:

Cost of vaccination = \$25 Will Vaccination Save Money? Probably not:			
	If <u>NO</u> infant disease	If <u>ALL</u> infant disease	

prevented

No

No

disease prevented

Adolescents Adols + boosters Adults at 20 yrs Adults + boosters


Policy option

No No No Cost of vaccination = \$25 Will Vaccination Be <u>Cost-Effective</u>? Cost < \$50,000 per QALY saved


Cost of vaccination = \$25 Will Vaccination Be <u>Cost-Effective</u>? Cost < \$50,000 per QALY saved

	If <u>NO</u> infant	If <u>ALL</u> infant
	disease	disease
Policy option	prevented	prevented
Adolescents	Yes	Yes
Adols + boosters	No	No
Adults at 20 yrs		Yes
Adults + boosters		

Sensitivity to Incidence of Pertussis and Cost of Vaccination



Sensitivity to Incidence of Pertussis and Cost of Vaccination



Preliminary Findings

- Tradeoffs depend greatly on:
 True incidence of disease
 - Cost of vaccination (including vaccine price and program costs)
 - Effects on infant disease

Messages

- Pertussis in adolescents and adults is increasing and costly
- Vaccination <u>could</u> be beneficial and cost-effective
- Need better data on incidence

Slides following this slide are leftovers


Markov Model

Full Immunity	
Some Immunity	
No Immunity	

Non-medical Costs

Adolescents (\$180)

Adults (\$570)



Outcome Measures

- Cases of pertussis prevented
- Adverse effects
- Total cost
- Life-years saved

- Quality-adjusted life-years saved
- \$ per QALY saved

Next Steps

Add a "cocoon" strategy to the model

 Need estimates of impact on infant disease from dynamic models

Include public health costs

Other Adolescent Time Costs

- 87% missed school due to illness
- Average days missed from school – 6.1 days (0.4-32 days)
- 27% of adolescents had jobs
- Average days missed from work
 4.8 days (0.5-15 days)

Public Health Costs

- Average costs of 3 states with high incidence of pertussis:
- Surveillance--\$202,000 per year
- Health care outbreak--\$33,000 per year
- School outbreak--\$21,000 per year
- Average cost per state--\$256,000
- Average cost for U.S.--\$12.8 million